92 research outputs found

    Visual Affect Around the World: A Large-scale Multilingual Visual Sentiment Ontology

    Get PDF
    Every culture and language is unique. Our work expressly focuses on the uniqueness of culture and language in relation to human affect, specifically sentiment and emotion semantics, and how they manifest in social multimedia. We develop sets of sentiment- and emotion-polarized visual concepts by adapting semantic structures called adjective-noun pairs, originally introduced by Borth et al. (2013), but in a multilingual context. We propose a new language-dependent method for automatic discovery of these adjective-noun constructs. We show how this pipeline can be applied on a social multimedia platform for the creation of a large-scale multilingual visual sentiment concept ontology (MVSO). Unlike the flat structure in Borth et al. (2013), our unified ontology is organized hierarchically by multilingual clusters of visually detectable nouns and subclusters of emotionally biased versions of these nouns. In addition, we present an image-based prediction task to show how generalizable language-specific models are in a multilingual context. A new, publicly available dataset of >15.6K sentiment-biased visual concepts across 12 languages with language-specific detector banks, >7.36M images and their metadata is also released.Comment: 11 pages, to appear at ACM MM'1

    Mass Varying Neutrinos, Quintessence, and the Accelerating Expansion of the Universe

    Full text link
    We analyze the Mass Varying Neutrino (MaVaN) scenario. We consider a minimal model of massless Dirac fermions coupled to a scalar field, mainly in the framework of finite temperature quantum field theory. We demonstrate that the mass equation we find has non-trivial solutions only for special classes of potentials, and only within certain temperature intervals. We give most of our results for the Ratra-Peebles Dark Energy (DE) potential. The thermal (temporal) evolution of the model is analyzed. Following the time arrow, the stable, metastable and unstable phases are predicted. The model predicts that the present Universe is below its critical temperature and accelerates. At the critical point the Universe undergoes a first-order phase transition from the (meta)stable oscillatory regime to the unstable rolling regime of the DE field. This conclusion agrees with the original idea of quintessence as a force making the Universe roll towards its true vacuum with zero \Lambda-term. The present MaVaN scenario is free from the coincidence problem, since both the DE density and the neutrino mass are determined by the scale M of the potential. Choosing M ~ 10^{-3} eV to match the present DE density, we can obtain the present neutrino mass in the range m ~ 10^{-2}-1 eV and consistent estimates for other parameters of the Universe.Comment: 29 pages, 7 figures. V. 3: Analysis of the dynamics of the Universe and some refs. added; extended version to be published in PR

    ОБВРАЯ ΠŸΠ ΠΠ’ΠžΠ–Π•Π›Π£Π”ΠžΠ§ΠšΠžΠ’ΠΠ― ΠΠ•Π”ΠžΠ‘Π’ΠΠ’ΠžΠ§ΠΠžΠ‘Π’Π¬

    Get PDF
    From the beginning of this century, clinicians started to pay more attention to the right ventricular dysfunction. It is related to the thorough studying of pathologies, during which the right ventricular dysfunction plays the key role, such as pulmonary hypertension, congenital heart disorders, andΒ thromboembolia of the pulmonary artery. Currently, it has been proved that acute right ventricular failure makes 3-9% of all acute heart failures, the hospital lethality in these clinical situations makes from 5 to 17%. The objective of the literature review is to provide anesthesiologists andΒ emergency physicians with information on modern approaches to diagnostics and treatment of acute right ventricular failure.The review presents data on normal anatomy and physiology of the right ventricle, morphological and functional changes when various forms ofΒ acute right ventricular failure develop. Diagnostics and comprehensive intensive care are described for the two most frequent types of acute right ventricular failure, which are reduction of right ventricular contractility and its overloading with afterload.Начало настоящСго столСтия характСризуСтся ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ΠΌ интСрСса со стороны клиницистов ΠΊ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ΅ дисфункции ΠΏΡ€Π°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ°. Бвязано это с Π³Π»ΡƒΠ±ΠΎΠΊΠΈΠΌ ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ΠΌ патологичСских состояний, Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠΈ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… поврСТдСния ΠΏΡ€Π°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ° носят ΠΊΠ»ΡŽΡ‡Π΅Π²ΡƒΡŽ Ρ€ΠΎΠ»ΡŒ, Ρ‚Π°ΠΊΠΈΡ… ΠΊΠ°ΠΊ лСгочная гипСртСнзия, Π²Ρ€ΠΎΠΆΠ΄Π΅Π½Π½Ρ‹Π΅ ΠΏΠΎΡ€ΠΎΠΊΠΈ сСрдца, тромбоэмболия Π»Π΅Π³ΠΎΡ‡Π½ΠΎΠΉ Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠΈ. БСгодня ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, Ρ‡Ρ‚ΠΎ срСди всСх случаСв острой сСрдСчной нСдостаточности Π½Π° долю острой ΠΏΡ€Π°Π²ΠΎΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠΎΠ²ΠΎΠΉ нСдостаточности приходится 3–9%, Π³ΠΎΡΠΏΠΈΡ‚Π°Π»ΡŒΠ½Π°Ρ Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Π² этих клиничСских ситуациях составляСт ΠΎΡ‚ 5 Π΄ΠΎ 17%. ЦСль ΠΎΠ±Π·ΠΎΡ€Π° Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ β€’ прСдоставлСниС анСстСзиологам-Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³Π°ΠΌ свСдСний ΠΎ соврСмСнных ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Π°Ρ… ΠΊ диагностикС ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΡŽ острой нСдостаточности ΠΏΡ€Π°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ°.Π’ ΠΎΠ±Π·ΠΎΡ€Π΅ ΠΏΡ€ΠΈΠ²Π΅Π΄Π΅Π½Ρ‹ Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ Π½ΠΎΡ€ΠΌΠ°Π»ΡŒΠ½ΠΎΠΉ Π°Π½Π°Ρ‚ΠΎΠΌΠΈΠΈ ΠΈ Ρ„ΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡ€Π°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ°, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΎ морфологичСских ΠΈ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹Ρ… измСнСниях ΠΏΡ€ΠΈ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… Ρ„ΠΎΡ€ΠΌ острой ΠΏΡ€Π°Π²ΠΎΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠΎΠ²ΠΎΠΉ нСдостаточности. Диагностика ΠΈ комплСксная интСнсивная тСрапия рассмотрСны для Π΄Π²ΡƒΡ… Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ распространСнных Ρ‚ΠΈΠΏΠΎΠ² острой ΠΏΡ€Π°Π²ΠΎΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠΎΠ²ΠΎΠΉ нСдостаточности – сниТСния ΡΠΎΠΊΡ€Π°Ρ‚ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ способности ΠΏΡ€Π°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ° ΠΈ Π΅Π³ΠΎ ΠΏΠ΅Ρ€Π΅Π³Ρ€ΡƒΠ·ΠΊΠΈ постнагрузкой

    ΠžΡ†Π΅Π½ΠΊΠ° риска ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡Π½ΠΎ-ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ кровотСчСния Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΠΎΠ²Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°

    Get PDF
    The aim of the study was to develop a risk model for upper gastrointestinal tract (GIT) bleeding in patients with brain injury of various etiologies.Material and methods. Case histories of 33 patients were included into a retrospective descriptive study: 22 patients had severe brain injury of various etiologies, and 11 patients after elective surgery for cerebral aneurisms with uneventful postop period were taken for comparison. The patients were grouped in two arms: Group 1 included patients with obvious signs of GIT bleeding (N=11) and Group 2 had no obvious signs of bleeding (N=22). Complaints, life and medical history, comorbidities, specialists’ exams data, results of laboratory and instrumental examinations, therapeutic regimens were analyzed. Presence of disproportionate pathologic sympathetic overreaction to acute brain injury, i.e., paroxysmal sympathetic hyperactivity (PSH), was assessed on admission and on Days 1, 3 and 5 after brain injury.Β Results. A model for upper GIT bleeding risk assessment was designed using logistic regression. The resulting model gains high quality rating: χ²=33,78, 3; p<0,001; OR=315. The risk of upper GIT bleeding exceeded 95% in patients having combination of 4 symptoms in their medical history (presence of PSH on Day 1 after acute brain injury; Karnofsky performance scale index 75; lack of neurovegetative stabilization in the acute period of brain injury; gastric and/or duodenal ulcer).Conclusion. Determining the risk factors thresholds enables stratification of patients by the risk for upper GIT bleeding. Modification of the identified four risk factors (presence of PSH on Day 1after acute brain injury; Karnofsky performance scale index 75; lack of neurovegetative stabilization in the acute period of brain injury; gastric and/or duodenal ulcer) will probably reduce the occurrence of upper GIT bleeding in patients with acute brane injury of various etiology.ЦСль исслСдования β€” построСниС ΠΌΠΎΠ΄Π΅Π»ΠΈ риска развития ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡Π½ΠΎ-ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ кровотСчСния ΠΈΠ· ΠΆΠ΅Π»ΡƒΠ΄ΠΊΠ° ΠΈ двСнадцатипСрстной кишки Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΠΎΠ²Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Ρ€Π°Π·Π»ΠΈΡ‡Π½ΠΎΠΉ этиологии.Β ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ рСтроспСктивноС ΠΎΠΏΠΈΡΠ°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠ΅ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡ΠΈΠ»ΠΈ истории Π±ΠΎΠ»Π΅Π·Π½ΠΈ 33-Ρ… ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ²: 22 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² β€” с тяТСлым ΠΏΠΎΠ²Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Ρ€Π°Π·Π»ΠΈΡ‡Π½ΠΎΠΉ этиологии ΠΈ, для сравнСния, 11 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² β€” с анСвризматичСской болСзнью сосудов Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° с нСослоТнСнным Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ΠΌ послСопСрационного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° послС ΠΏΠ»Π°Π½ΠΎΠ²Ρ‹Ρ… нСйрохирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π². ВсСх ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Ρ€Π°Π·Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π° 2 Π³Ρ€ΡƒΠΏΠΏΡ‹: с явными ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ кровотСчСния ΠΈΠ· Π–ΠšΠ’ (n=11) ΠΈ Π±Π΅Π· явных ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠΎΠ² кровотСчСния (n=22). ΠŸΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π»ΠΈ ΠΆΠ°Π»ΠΎΠ±Ρ‹, Π°Π½Π°ΠΌΠ½Π΅Π· заболСвания ΠΈ ΠΆΠΈΠ·Π½ΠΈ, ΡΠΎΠΏΡƒΡ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΠ΅ заболСвания, Π΄Π°Π½Π½Ρ‹Π΅ осмотров спСциалистов, Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΈ ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исслСдований, особСнности Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ. Π€ΡƒΠ½ΠΊΡ†ΠΈΠΈ Π²Π΅Π³Π΅Ρ‚Π°Ρ‚ΠΈΠ²Π½ΠΎΠΉ Π½Π΅Ρ€Π²Π½ΠΎΠΉ систСмы ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ проявлСниям ΠΏΠ°Ρ€ΠΎΠΊΡΠΈΠ·ΠΌΠ°Π»ΡŒΠ½ΠΎΠΉ симпатичСской гипСрактивности (ΠŸΠ‘Π“Π) ΠΏΡ€ΠΈ поступлСнии Π² стационар, Π½Π° 1-Π΅, 3-ΠΈ ΠΈ 5-Π΅ сут послС поврСТдСния Π“Πœ.Β Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. БрСдствами логистичСской рСгрСссии построили модСль ΠΎΡ†Π΅Π½ΠΊΠΈ риска развития явного кровотСчСния ΠΈΠ· Π²Π΅Ρ€Ρ…Π½ΠΈΡ… ΠΎΡ‚Π΄Π΅Π»ΠΎΠ² ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡Π½ΠΎ-ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ Ρ‚Ρ€Π°ΠΊΡ‚Π°. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Π°Ρ модСль ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ‚ высокой ΠΎΡ†Π΅Π½ΠΊΠΎΠΉ качСства: χ²=33,78, 3; p<0,001; OR=315. ΠŸΡ€ΠΈ сочСтании Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ 4-Ρ… ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠΎΠ² (ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ ΠŸΠ‘Π“Π Π² 1-Π΅ сут послС поврСТдСния Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°; индСкс ΠšΠ°Ρ€Π½ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅Π½Π΅Π΅ 75; отсутствиС Π½Π΅ΠΉΡ€ΠΎΠ²Π΅Π³Π΅Ρ‚Π°Ρ‚ΠΈΠ²Π½ΠΎΠΉ стабилизации Π² остром ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ поврСТдСния Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°; язвСнная болСзнь ΠΆΠ΅Π»ΡƒΠ΄ΠΊΠ° ΠΈ двСнадцатипСрстной кишки (Π”ΠŸΠš)) риск развития явного кровотСчСния ΠΈΠ· Π²Π΅Ρ€Ρ…Π½ΠΈΡ… ΠΎΡ‚Π΄Π΅Π»ΠΎΠ² ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡Π½ΠΎ-ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ Ρ‚Ρ€Π°ΠΊΡ‚Π° ΠΏΡ€Π΅Π²Ρ‹ΡˆΠ°Π» 95%.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π’Ρ‹Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΡ€ΠΎΠ³ΠΎΠ²Ρ‹Ρ… Π·Π½Π°Ρ‡Π΅Π½ΠΈΠΉ Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² риска позволяСт Ρ€Π°Π·Π΄Π΅Π»ΠΈΡ‚ΡŒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π½Π° Π³Ρ€ΡƒΠΏΠΏΡ‹ риска развития ΠΊΡ€ΠΎΠ²ΠΎΡ‚Π΅Ρ‡Π΅Π½ΠΈΠΉ ΠΈΠ· Π²Π΅Ρ€Ρ…Π½ΠΈΡ… ΠΎΡ‚Π΄Π΅Π»ΠΎΠ² Π–ΠšΠ’. ВоздСйствиС Π½Π° выявлСнныС 4 Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° риска (проявлСния ΠŸΠ‘Π“Π Π² 1-Π΅ сут послС поврСТдСния Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°; индСкс ΠšΠ°Ρ€Π½ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅Π½Π΅Π΅ 75; отсутствиС Π½Π΅ΠΉΡ€ΠΎΠ²Π΅Π³Π΅Ρ‚Π°Ρ‚ΠΈΠ²Π½ΠΎΠΉ стабилизации Π² остром ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ поврСТдСния Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°; язвСнная болСзнь ΠΆΠ΅Π»ΡƒΠ΄ΠΊΠ° ΠΈ Π”ΠŸΠš) ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ‚, вСроятно, ΡΠ½ΠΈΠ·ΠΈΡ‚ΡŒ частоту Π–ΠšΠš ΠΈΠ· Π²Π΅Ρ€Ρ…Π½ΠΈΡ… ΠΎΡ‚Π΄Π΅Π»ΠΎΠ² Π–ΠšΠ’ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΠΎΠ²Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π“Πœ Ρ€Π°Π·Π»ΠΈΡ‡Π½ΠΎΠΉ этиологии.

    Surfactant therapy for pneumonia COVID-19 of obstetric patients

    Get PDF
    Introduction. Pregnant women may be at increased risk forΒ severe COVID-19 illness. Pregnant women are more likely to be hospitalized at ICU, needed theΒ mechanical ventilation compared to nonpregnant women ofΒ childbearing age. Building on theΒ experience ofΒ the effective use ofΒ the exogenous surfactant forΒ influenza A/H1N1Β treatment ofΒ pregnant women with COVID-19, theΒ surfactant therapy has also been included inΒ the treatment.The objective. To evaluate theΒ effectiveness ofΒ surfactant therapy inΒ the integrated treatment ofΒ severe COVID-19 pneumonia ofΒ pregnant women and postpartum women.Materials and methods. The study included 135Β pregnant and postpartum women with severe COVID-19 pneumonia. All ofΒ them received antiviral, anticoagulant, anticytokine and anti-inflammatory therapy. 68Β patients (main group) with an initially more severe course ofΒ the disease and aΒ greater degree ofΒ lung damage (pΒ = 0.026) received inhalations with Surfactant-BL, 67Β patients (control group) did not receive theΒ  surfactant therapy. Patients received Surfactant-BL through aΒ  mesh-nebulizer at aΒ  dose ofΒ 75Β mg 2Β times aΒ day forΒ 3–5Β days.Result. Patients ofΒ the main group showed decreasing risks ofΒ requiring theΒ noninvasive ventilation (27.9% vs. 52.2%, Ρ€Β = 0.014) and artificial lung ventilation (2.9% vs. 11.9%, pΒ = 0.047), theΒ length ofΒ stay inΒ the intensive care unit (ICU) was reduced (10.6Β vs. 13.1Β inpatient days, Ρ€Β = 0.045). Π‘omplications such as pneumomediastinum and pneumothorax occurred less frequently inΒ the surfactant therapy group (24.2% vs. 52.4%, pΒ = 0.037) with aΒ high extent ofΒ lung damage (CT-3–4). With early surfactant therapy inΒ the standard oxygen therapy stage or high-flow oxygenation, gas exchange indicators were restored faster, thus avoiding mechanical ventilation and has reduced theΒ duration ofΒ intensive care (Ρ€ = 0.004) and prevented deaths.Conclusion. The use ofΒ surfactant therapy forΒ pneumonia associated with COVID-19 inΒ pregnant and postpartum women against theΒ background ofΒ ongoing complex therapy helps to prevent further lung damage, reduce theΒ mechanical ventilation risk and improve oxygenation earlier, especially with early start ofΒ surfactant therapy

    ВлияниС ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² ΠΎΠ±Ρ‰Π΅ΠΉ анСстСзии Π½Π° систСмный Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ ΠΎΡ‚Π²Π΅Ρ‚ ΠΏΡ€ΠΈ кардиохирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π°Ρ…

    Get PDF
    Systemic inflammatory response syndrome (SIRS) is a severe complication in surgical patients associated with increased morbidity and mortality. Anesthetics are known to produce certain effects on the immune system and the manifestation of SIRS. The understanding of these beneficial mechanisms allows selecting optimal anesthetics in order to reduce the manifestation of SIRS and infectious complications in the postoperative period.БистСмный Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ ΠΎΡ‚Π²Π΅Ρ‚ (Π‘Π’Πž) являСтся Π³Ρ€ΠΎΠ·Π½Ρ‹ΠΌ ослоТнСниСм хирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π², ΡƒΠ²Π΅Π»ΠΈΡ‡ΠΈΠ²Π°ΡŽΡ‰ΠΈΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡ‚ΡŒ ΠΈ ΡΠΌΠ΅Ρ€Ρ‚Π½ΠΎΡΡ‚ΡŒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². Π˜Π·Π²Π΅ΡΡ‚Π½ΠΎ, Ρ‡Ρ‚ΠΎ анСстСтики ΠΎΠ±Π»Π°Π΄Π°ΡŽΡ‚ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡ‚ΡŒΡŽ Π²Π»ΠΈΡΡ‚ΡŒ Π½Π° ΠΈΠΌΠΌΡƒΠ½Π½ΡƒΡŽ систСму ΠΈ проявлСниС Π‘Π’Πž. Π—Π½Π°Π½ΠΈΠ΅ ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΏΠΎΠ΄ΠΎΠ±Π½ΠΎΠ³ΠΎ влияния являСтся клиничСски Π²Π°ΠΆΠ½Ρ‹ΠΌ условиСм ΠΏΡ€Π°Π²ΠΈΠ»ΡŒΠ½ΠΎΠ³ΠΎ Π²Ρ‹Π±ΠΎΡ€Π° ΠΈ примСнСния анСстСтика с Ρ†Π΅Π»ΡŒΡŽ сниТСния проявлСния Π‘Π’Πž ΠΈ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний Π² послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅

    A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure. an expert panel consensus

    Get PDF
    Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure

    Π ΠΠ—Π›Π˜Π§ΠΠžΠ• Π’Π›Π˜Π―ΠΠ˜Π• ΠΠΠ ΠšΠžΠ’Π˜Π§Π•Π‘ΠšΠ˜Π₯ ΠΠΠΠ›Π¬Π“Π•Π’Π˜ΠšΠžΠ’ НА Π”Π˜ΠΠΠœΠ˜ΠšΠ£ ΠΠšΠ’Π˜Π’ΠΠžΠ‘Π’Π˜ Π¦Π˜Π’ΠžΠšΠ˜ΠΠžΠ’ Π’Πž Π’Π Π•ΠœΠ― ΠšΠΠ Π”Π˜ΠžΠ₯Π˜Π Π£Π Π“Π˜Π§Π•Π‘ΠšΠ˜Π₯ Π’ΠœΠ•Π¨ΠΠ’Π•Π›Π¬Π‘Π’Π’ Π’ Π£Π‘Π›ΠžΠ’Π˜Π―Π₯ Π˜Π‘ΠšΠ£Π‘Π‘Π’Π’Π•ΠΠΠžΠ“Πž ΠšΠ ΠžΠ’ΠžΠžΠ‘Π ΠΠ©Π•ΠΠ˜Π―

    Get PDF
    According to experimental data, morphine possesses certain anti-inflammatory properties, which can reduce the manifestations of system inflammatory response (SIR) after cardiopulmonary bypass. Objective: to investigate the effect of various narcotic analgesics on the activity of some SIR markers during peri-operative period of cardiac surgery with cardiopulmonary bypass. Subjects and methods. During the one-centered randomized prospective study, the changes in the concentration of interleukin-6, (IL-6), interleukin-8 (IL-8) and tumor necrosis factor (TNF) were followed up before cardiopulmonary bypass, and in 1, 3 and 24 hours after it in 60 patients, randomly divided into 2 groups. Patients of Group 1 (n = 30) received anesthesia with phentanyl, those from Group 2 (n = 30) received morphine. The groups did not differ in their clinical and demographic parameters and surgery types, performed in them. Results. The significant increase in the concentration of all inflammatory markers was observed in 1 hour after cardiopulmonary bypass was off, which was the evidence of SIR development. In the Group on morphine, the activity of markers was lower versus the Group on phentanyl. Thus, concentration of IL-6 in 3 hours after cardiopulmonary bypass made 155 (113; 180) versus 178 (102; 236) pg/ml (p = 0.006), IL-8 in 1 hour after cardiopulmonary bypass made 37.4 (25.4; 50.2) versus 52.6 (24; 91.4) pg/ml (p = 0,03), in 1 hour the level of TNF achieved 10.7 (8.6; 15.9) versus 15.7 (11.4; 23.1) pg/ml (p = 0.01), and in 3 hours it made βˆ’ 9.7 (8.3; 13.8) versus 14.1 (9.6; 18.8) pg/ml (p = 0.04). However, there was no difference in the clinical course parameters between the Groups. Conclusion. The obtained results prove the morphine potential to reduce the expression of pro-inflammatory markers when used during cardiac surgery with cardiopulmonary bypass. Богласно ΡΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹ΠΌ Π΄Π°Π½Π½Ρ‹ΠΌ, ΠΌΠΎΡ€Ρ„ΠΈΠ½ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ‚ ΠΏΡ€ΠΎΡ‚ΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌΠΈ свойствами, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΠΌΠΎΠ³ΡƒΡ‚ ΡΠ½ΠΈΠ·ΠΈΡ‚ΡŒ проявлСния систСмного Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΎΡ‚Π²Π΅Ρ‚Π° (Π‘Π’Πž) послС ΠΏΡ€ΠΎΡ†Π΅Π΄ΡƒΡ€ искусствСнного кровообращСния (ИК). ЦСль: ΠΈΠ·ΡƒΡ‡ΠΈΡ‚ΡŒ влияниС Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… наркотичСских Π°Π½Π°Π»ΡŒΠ³Π΅Ρ‚ΠΈΠΊΠΎΠ² Π½Π° Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π½Π΅ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² Π‘Π’Πž Π² ΠΏΠ΅Ρ€ΠΈΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅ кардиохирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π², Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Π½Ρ‹Ρ… Π² условиях ИК. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ Ρ…ΠΎΠ΄Π΅ ΠΎΠ΄Π½ΠΎΡ†Π΅Π½Ρ‚Ρ€ΠΎΠ²ΠΎΠ³ΠΎ, Ρ€Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ, проспСктивного исслСдования ΠΈΠ·ΡƒΡ‡Π°Π»ΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½Π°-6 (Π˜Π›-6), ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½Π°-8 (Π˜Π›-8) ΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° Π½Π΅ΠΊΡ€ΠΎΠ·Π° ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ (ЀНО) Π΄ΠΎ ИК, Ρ‡Π΅Ρ€Π΅Π· 1, 3 ΠΈ 24 Ρ‡ послС окончания ИК Ρƒ 60Β ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Ρ€Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… Π² Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ (n = 30) ΠΏΠΎΠ»ΡƒΡ‡Π°Π»ΠΈ Π°Π½Π΅ΡΡ‚Π΅Π·ΠΈΡŽ с использованиСм Ρ„Π΅Π½Ρ‚Π°Π½ΠΈΠ»Π°, 2-ΠΉ (n =Β 30)Β βˆ’ с примСнСниСм ΠΌΠΎΡ€Ρ„ΠΈΠ½Π°. Π“Ρ€ΡƒΠΏΠΏΡ‹ Π½Π΅ Ρ€Π°Π·Π»ΠΈΡ‡Π°Π»ΠΈΡΡŒ ΠΏΠΎ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-дСмографичСским показатСлям ΠΈ характСристикам ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΉ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠžΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½ΠΎ Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΠ΅ ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ всСх ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² воспалСния ΡƒΠΆΠ΅ Ρ‡Π΅Ρ€Π΅Π· 1 Ρ‡ послС ΠΎΡ‚ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ ИК Π² ΠΎΠ±Π΅ΠΈΡ… Π³Ρ€ΡƒΠΏΠΏΠ°Ρ…, Ρ‡Ρ‚ΠΎ ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎΠ²Π°Π»ΠΎ ΠΎ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠΈ Π‘Π’Πž. Π’ Π³Ρ€ΡƒΠΏΠΏΠ΅ ΠΌΠΎΡ€Ρ„ΠΈΠ½Π° Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² Π±Ρ‹Π»Π° Π½ΠΈΠΆΠ΅, Ρ‡Π΅ΠΌ Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ Ρ„Π΅Π½Ρ‚Π°Π½ΠΈΠ»Π°. Π’Π°ΠΊ, концСнтрация Π˜Π›-6 Ρ‡Π΅Ρ€Π΅Π· 3 Ρ‡ послС ИК составляла 155 (113; 180) ΠΏΡ€ΠΎΡ‚ΠΈΠ² 178 (102; 236) ΠΏΠ³/ΠΌΠ» (p = 0,006), Π˜Π›-8 Ρ‡Π΅Ρ€Π΅Π· 1 Ρ‡ послС ИК βˆ’ 37,4Β (25,4;Β 50,2) ΠΏΡ€ΠΎΡ‚ΠΈΠ² 52,6 (24; 91,4) ΠΏΠ³/ΠΌΠ» (p = 0,03), ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ЀНО Ρ‡Π΅Ρ€Π΅Π· 1 Ρ‡ достиг 10,7 (8,6; 15,9) ΠΏΡ€ΠΎΡ‚ΠΈΠ² 15,7 (11,4; 23,1) ΠΏΠ³/ΠΌΠ» (p = 0,01), Ρ‡Π΅Ρ€Π΅Π· 3Β Ρ‡Β βˆ’ 9,7Β (8,3; 13,8) ΠΏΡ€ΠΎΡ‚ΠΈΠ² 14,1 (9,6; 18,8) ΠΏΠ³/ΠΌΠ» (p = 0,04). Однако Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ Π² показатСлях клиничСского тСчСния ΠΌΠ΅ΠΆΠ΄Ρƒ Π³Ρ€ΡƒΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ Π±Ρ‹Π»ΠΎ. Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΏΠΎΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‚ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡ‚ΡŒ ΠΌΠΎΡ€Ρ„ΠΈΠ½Π° ΡΠ½ΠΈΠΆΠ°Ρ‚ΡŒ ΡΠΊΡΠΏΡ€Π΅ΡΡΠΈΡŽ ΠΏΡ€ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² ΠΏΡ€ΠΈ использовании Π²ΠΎ врСмя кардиохирургичСских Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π² Π² условиях ИК.

    ΠœΠΎΠ΄ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ Π΄Π΅Π»ΡŒΡ„ΠΈΠΉΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ ΠΈ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² качСства мСтодичСских Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΉ ΠžΠ±Ρ‰Π΅Ρ€ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ общСствСнной ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΈ «ЀСдСрация анСстСзиологов ΠΈ Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ²Β» Β«ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠΉ вСнтиляции Π»Π΅Π³ΠΊΠΈΡ…Β»

    Get PDF
    ΠΠšΠ’Π£ΠΠ›Π¬ΠΠžΠ‘Π’Π¬: ΠΠ΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ нСзависимой ΠΎΡ†Π΅Π½ΠΊΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΉ ΠΏΠ΅Ρ€Π΅Π΄ ΠΈΡ… ΠΏΠ»Π°Π½ΠΎΠ²Ρ‹ΠΌ пСрСсмотром Π½Π° основС стороннСго мнСния ΠΊΠΎΠΌΠΏΠ΅Ρ‚Π΅Π½Ρ‚Π½Ρ‹Ρ… спСциалистов Π½Π΅ Π²Ρ‹Π·Ρ‹Π²Π°Π΅Ρ‚ сомнСний. Π”Π°Π½Π½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ· позволяСт Π°Π΄Π°ΠΏΡ‚ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΡŽ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΉ Π½Π° Ρ€Π°Π±ΠΎΡ‡ΠΈΡ… мСстах с ΡƒΡ‡Π΅Ρ‚ΠΎΠΌ особСнностСй оснащСния ΠΈΒ Π·Π½Π°Π½ΠΈΠΉ спСциалистов. Π¦Π•Π›Π¬ Π˜Π‘Π‘Π›Π•Π”ΠžΠ’ΠΠΠ˜Π―: ΠŸΡ€ΠΎΠ²Π΅ΡΡ‚ΠΈ Π°Π½Π°Π»ΠΈΠ· эффСктивности, бСзопасности и доступности выполнСния в клиничСской ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅ мСтодичСских Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΉ Β«ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠΉ вСнтиляции Π»Π΅Π³ΠΊΠΈΡ…Β» с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΠΌΠΎΠ΄ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Π° Π”Π΅Π»ΡŒΡ„ΠΈ. ΠœΠΠ’Π•Π Π˜ΠΠ›Π« И ΠœΠ•Π’ΠžΠ”Π«: ЭкспСртная ΠΎΡ†Π΅Π½ΠΊΠ° Π±Ρ‹Π»Π° ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΏΠΎ ΠΈΠ½ΠΈΡ†ΠΈΠ°Ρ‚ΠΈΠ²Π΅ ΠΊΠΎΠΌΠΈΡ‚Π΅Ρ‚Π° ΠΏΠΎ рСкомСндациям ΠΈΒ ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΈ исслСдований ΠžΠ±Ρ‰Π΅Ρ€ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ общСствСнной ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΈ «ЀСдСрация анСстСзиологов ΠΈΒ Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ²Β» и состояла ΠΈΠ· Ρ‚Ρ€Π΅Ρ… этапов. ΠŸΠΎΠ΄Π³ΠΎΡ‚ΠΎΠ²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ этап Π·Π°ΠΊΠ»ΡŽΡ‡Π°Π»ΡΡ Π²Β Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΊΠΎΠΎΡ€Π΄ΠΈΠ½Π°Ρ‚ΠΎΡ€ΠΎΠΌ экспСртизы мСтодичСской Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ Β«ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠΉ вСнтиляции Π»Π΅Π³ΠΊΠΈΡ…Β» ΠΈΒ ΠΎΡ„ΠΎΡ€ΠΌΠ»Π΅Π½ΠΈΠΈ Π°Π½ΠΊΠ΅Ρ‚Ρ‹-опросника, состоящСй ΠΈΠ· Ρ‚Ρ€Π΅Ρ… Ρ€Π°Π·Π΄Π΅Π»ΠΎΠ²: ΠΎΡ†Π΅Π½ΠΊΠ° тСзис-Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΉ; ΠΎΡ†Π΅Π½ΠΊΠ° ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² качСства мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ и общая ΠΎΡ†Π΅Π½ΠΊΠ° мСтодичСской Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ. На основном этапС разослана Π°Π½ΠΊΠ΅Ρ‚Π°, и рСспондСнтам ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΎ ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ полоТСния ΠΏΠΎ Π΄Π΅ΡΡΡ‚ΠΈΠ±Π°Π»Π»ΡŒΠ½ΠΎΠΉ шкалС Π .Β Π›Π°ΠΉΠΊΠ΅Ρ€Ρ‚Π°. АналитичСский этап Π·Π°ΠΊΠ»ΡŽΡ‡Π°Π»ΡΡ в расчСтС ΡΡ€Π΅Π΄Π½Π΅Π²Π·Π²Π΅ΡˆΠ΅Π½Π½ΠΎΠΉ ΠΎΡ†Π΅Π½ΠΊΠΈ, ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ‹ ΠΈΒ ΠΌΠΎΠ΄Ρ‹. ΠŸΡ€ΠΈ ΠΎΡ†Π΅Π½ΠΊΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ ΠΈΒ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² качСства оказания мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ ΡƒΡ‡ΠΈΡ‚Ρ‹Π²Π°Π»ΠΈΡΡŒ Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ‹ ΠΈΠ»ΠΈ ΠΌΠΎΠ΄Ρ‹ любого полоТСния, ΡΡ€Π΅Π΄Π½Π΅Π²Π·Π²Π΅ΡˆΠ΅Π½Π½Π°Ρ ΠΎΡ†Π΅Π½ΠΊΠ°; Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ‹ ΠΈΠ»ΠΈ ΠΌΠΎΠ΄Ρ‹ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² качСства оказания мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ, ΡΡ€Π΅Π΄Π½Π΅Π²Π·Π²Π΅ΡˆΠ΅Π½Π½Π°Ρ ΠΎΡ†Π΅Π½ΠΊΠ°. РЕЗУЛЬВАВЫ: В экспСртизС приняли участиС 15 спСциалистов. ΠžΡΠ½ΠΎΠ²Π½Ρ‹Π΅ замСчания и дополнСния Π·Π°ΠΊΠ»ΡŽΡ‡Π°Π»ΠΈΡΡŒ Π²Β ΡƒΡ‚ΠΎΡ‡Π½Π΅Π½ΠΈΠΈ Ρ‚Π΅Ρ€ΠΌΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΊΠΎΠ½ΠΊΡ€Π΅Ρ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ и стилистики. Участники Π΄Π΅Π»ΡŒΡ„ΠΈΠΉΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΠ»ΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ в клиничСской ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ мСтодичСской Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ. Π”Π΅Ρ„ΠΈΡ†ΠΈΡ‚ оборудования Π΄Π΅Π»Π°Π΅Ρ‚ ΠΎΠ³Ρ€Π°Π½ΠΈΡ‡Π΅Π½Π½ΠΎ Π²Ρ‹ΠΏΠΎΠ»Π½ΠΈΠΌΡ‹ΠΌΠΈ Π»Π΅Ρ‡Π΅Π±Π½Ρ‹Π΅ мСроприятия. Π­Ρ‚ΠΎΡ‚ Ρ„Π°ΠΊΡ‚ ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€ΠΆΠ΄Π°Π΅Ρ‚ Π½ΠΈΠ·ΠΊΠΈΠ΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ cΡ€Π΅Π΄Π½Π΅Π²Π·Π²Π΅ΡˆΠ΅Π½Π½ΠΎΠΉ ΠΎΡ†Π΅Π½ΠΊΠΈ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² качСства оказания мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ. Π’Π«Π’ΠžΠ”Π«: Достигнут консСнсус ΠΏΠΎ 20 ΠΈΠ· 21 тСзис-Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ, ΠΏΠΎ 4 ΠΈΠ· 8 ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² качСства оказания мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ ΠΈΒ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½Ρ‹ΠΌ Ρ„ΠΎΡ€ΠΌΡƒΠ»ΠΈΡ€ΠΎΠ²ΠΊΠ°ΠΌ ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ. Π”Π΅Π»ΡŒΡ„ΠΈΠΉΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΏΠΎΡΠΌΠΎΡ‚Ρ€Π΅Ρ‚ΡŒ Π½Π° Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΡŽ мСтодичСской Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ с ΠΏΠΎΠ·ΠΈΡ†ΠΈΠΈ ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΡƒΡŽΡ‰ΠΈΡ… Π²Ρ€Π°Ρ‡Π΅ΠΉΒ β€” анСстСзиологов-Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ², Π²Β Ρ‚ΠΎΠΌ числС в структурных подраздСлСниях с Π½ΠΈΠ·ΠΊΠΈΠΌ ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎ-тСхничСской оснащСнности
    • …
    corecore